From GlobeNewswire: 2025-02-14 17:27:19

Bavarian Nordic A/S received FDA approval for VIMKUNYA™, the first single-dose chikungunya vaccine in the US for individuals aged 12 and older. The vaccine is based on virus-like particles and showed efficacy in producing neutralizing antibodies in up to 97.8% of vaccinated individuals. The vaccine is expected to be commercially launched in the US in the first half of 2025. Additional clinical studies will be conducted to confirm the vaccine’s clinical profile. VIMKUNYA will also be launched in key European markets once final marketing authorization is granted by the European Commission. Chikungunya is a mosquito-borne disease caused by the chikungunya virus, with over 480,000 cases reported globally in 2024.



Read more at GlobeNewswire: Bavarian Nordics chikungunyavaccine er blevet godkendt af